Goldman Sachs
SUPN icon

Goldman Sachs’s Supernus Pharmaceuticals SUPN Stock Holding History

Goldman Sachs’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-38,500
Closed -$1.91M – 6955
2025
Q4 		$1.91M Buy
+38,500
New +$1.87M ﹤0.01% 4633

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Goldman Sachs's SUPN Position: Q2 2026 in Review

Goldman Sachs reduced its Supernus Pharmaceuticals (SUPN) stake by 4.3% in Q2 2026, selling an estimated $1.78M and leaving 819,432 shares worth $38.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2042.

Goldman Sachs first reported a position in SUPN in Q4 2013 and has held it in 50 quarters since. The position peaked at $55.6M in Q3 2025. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Goldman Sachs held 819,432 shares of Supernus Pharmaceuticals worth $38.1M as of Q2 2026.
  • Goldman Sachs sold 37,055 Supernus Pharmaceuticals shares in Q2 2026, an estimated $1.78M.
  • Supernus Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2042 holding.
  • Goldman Sachs first reported a position in Supernus Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
  • Goldman Sachs's Supernus Pharmaceuticals position peaked at $55.6M in Q3 2025.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.